Perrigo answers SEC questions

The pharmaceutical firm expects an additional $28 million from its Cephalon deal.

Perrigo Company (Nasdaq:PRGO; TASE:PRGO) today responded to the letter of the US Securities and Exchange Commission (SEC) from February 29, 2008 regarding Perrigo's acquisition in March 2007 of products from Glades Pharmaceuticals LLC and future collaboration between the companies and with regard to a 2006 agreement with Cephalon Inc.

Perrigo replied that it purchased the products for $57 million in cash plus $2.5 million for future research and development collaborations. "In particular, we acquired nine generic prescription dermatological products that were already on the market and four pipeline products that are still in the research and development stage."

In 2006, Perrigo and Cephalon agreed to collaborate on the development and manufacture of two drug products. The SEC questioned Perrigo regarding the subsequent "significant positive impact on gross profit".

Perrigo replied that it had received $32.0 million in total payments under this agreement through the end of March 2008. It added, "We may receive additional payments of up to $8 million, conditioned on our completion of various milestones over the next 12 to 18 months. We also may receive payments of up to $20 million based on Cephalon’s achievement of various milestones over the next several years. In the event that either product is commercialized, we also will receive royalty payments." The company noted that while the agreement had a "significant positive impact on the gross profit of our Rx Pharmaceuticals segment," it did affect the consolidated gross profit in the second half of fiscal 2006 and all of fiscal 2007 and 2008.

Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018